AlphAIAlphAI — Financial news for AI agents
investing.com$TRNS

Northland upgrades Transcat stock rating on valuation, support

Northland upgraded Transcat (TRNS) to Outperform with a $95 price target, citing valuation and technical support. TRNS trades at $81.71 with a P/E of 227.43, showing 20.91% revenue growth. Q2 fiscal 2027 results are due Nov 17. Q1 results beat expectations with $0.51 EPS and $92.9M revenue, up 22% YoY.

Original reporting
investing.com
Published Oct 21, 2026, 11:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TRNS
Bullish
medium confidence
Mentioned
$TRNS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TRNSBullishMed
01

Why it matters

The upgrade could trigger short-term buying pressure, especially ahead of the upcoming Q2 earnings release.

02

Market read

Analyst upgrade adds fresh positive sentiment for TRNS, potentially influencing short-term price action.

03

What to watch

High P/E of 227 suggests risk if growth slows.

Relevance 7/10Novelty 7/10Timing: today

Background

Transcat provides calibration services and distributes test and measurement instruments, reporting strong Q1 revenue growth.

Company-level read

Ticker impact

$TRNSBullishMedium confidence
Context

Northland upgraded Transcat Inc. to Outperform and kept a $95 price target, a fresh analyst rating change.

Expected impact

likely upward pressure as investors price in the higher rating and $95 target

Evidence & confidence

Analyst cites valuation support and strong fundamentals, which can attract buying.

Market effects

Sector

Positive signal for the test and measurement instrumentation sector.

Regional

Limited to U.S. investors focused on small-cap industrials.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Upgrade may be premature if valuation remains stretched.

Key entities

  • Analyst Firm
    Northland

    Research firm issuing the upgrade.

  • Company
    Transcat Inc.

    Subject of the upgrade and earnings report.

Read at source← All news

Related articles

$TRNSMedAI 8/10

Transcat (TRNS) Q2 2027 Earnings Call Transcript

Transcat (TRNS) reported Q2 2027 revenue of $97.1M, up 18%, with service revenue growing 23% and distribution revenue up 10%. Gross profit increased 22%, and adjusted EBITDA grew 23% to $14.9M. The company cited strong demand in regulated end markets and strategic acquisitions, including Southeastern Biomedical Associates, as drivers of growth. Service gross margins expanded 220 basis points to 34.4%.

finance.yahoo.com
$TRNSMed

Transcat Q2 Earnings Call Highlights

Transcat (TRNS) reported Q2 growth in distribution revenue (10% to $32.3M) and adjusted EBITDA (23% to $14.9M). Management raised its fiscal 2027 service organic revenue growth outlook to low-double-digits and expects service gross-margin expansion. The company highlighted demand in regulated markets and completed an acquisition to expand its biomedical calibration footprint.

finance.yahoo.com
$TRNSMed

Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin…

TRANSCAT INC (TRNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE Transcat, Inc. 35 Vantage Point Drive • Rochester • NY • 14624 • Phone: (585) 352-7777 Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Significant Service Gross Margin Expansion •

SEC EDGAR 8-K
$TRNSMed

Transcat’s (NASDAQ:TRNS) Q2 CY2026: Strong Sales

Transcat (NASDAQ:TRNS) reported Q2 CY2026 results. Revenue rose 21.6% year on year to $92.95 million, topping Wall Street estimates by 7.4%. Non-GAAP adjusted EPS was $0.51, up 35.1% versus analysts’ consensus and down from $0.59 a year earlier. Analysts expect revenue to grow about 6% over the next 12 months.

financialcontent.com